article thumbnail

How Real-World Data Supports Pharmaceutical Drug Development

IT Toolbox

The post How Real-World Data Supports Pharmaceutical Drug Development appeared first on Spiceworks. Real-world Data (RWD) answers questions that clinical trials can’t answer.

article thumbnail

Best Training Methods for the Pharmaceutical Industry

Kitaboo

Pharmaceutical Industry today, is a goldmine of opportunities. The global pharmaceutical market was estimated at approximately $935 billion in 2017 and is bound to reach $1170 billion by 2021. And for a company to succeed, the people who make it, i.e., its employees, should be updated with all the recent developments.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Zymeworks nabs $350M from Jazz Pharmaceuticals after release of clinical trial data

GeekWire

Zymeworks will receive $350 million from Jazz Pharmaceuticals in return for the right to develop and commercialize Zymeworks’ lead drug candidate, zanidatamab, in the U.S., Europe and Japan.

article thumbnail

Biggest roadblocks that AI-powered drug development faced in 2022

Dataconomy

AI-powered drug development can shorten the time it takes to acquire and access information, cutting pharmaceutical development time in half and keeping the cost of new medications under control. This is becoming increasingly crucial as the cost of discovering and developing new drugs rises.

article thumbnail

Can developer productivity be measured? Better than you think

CIO Business Intelligence

Measuring developer productivity has long been a Holy Grail of business. In 2020, McKinsey surveyed 440 large companies about their “ developer velocity” — meaning the practices that best tap the full potential of development talent. Right now, there are roughly 27 million developers on the job, 4.4 That isn’t easy.

article thumbnail

Tadataka Yamada, 1945-2021: Pioneer in drug development led global health at Gates Foundation

GeekWire

Tadataka Yamada, a pioneer in drug and vaccine development who helped forge numerous biotech companies and spent six years at the Bill and Melinda Gates Foundation as head of global health, died Wednesday morning of natural causes at his home in Seattle. Tadataka “Tachi” Yamada. Twitter Photo via @TachiYamada).

article thumbnail

Vertex will buy Alpine Immune Sciences for $4.9B in another big Seattle biotech deal

GeekWire

AIS Photo) Boston-based biotech company Vertex Pharmaceuticals agreed to acquire Seattle-based Alpine Immune Sciences for $65 per share, totaling about $4.9 The company launched in 2015 and went public in 2017 through a merger with publicly traded pharmaceutical company Nivalis. Alpine Immune Sciences CEO Mitchell Gold in 2017.